Development of a Homogenous RSV Neutralization Assay on the Mirrorball Fluorescence Cytometer: A Simple, Safe and Robust Approach for High-throughput Screening
Human respiratory syncytial virus (RSV) is a syncytial virus that can cause serious respiratory tract infections, especially in infants and young children[1].
To date there is no licensed vaccine against RSV infection and the only preventative treatment option is the neutralizing anitbody palivizumab, which is given to high risk infants by passive administration[2]. Therefore there is a strong drive to identify novel RSV-neutralizing antibodies for therapeutic/preventative applications.
Here we present the development and implementation of a simple RSV-neutralization assay on TTP Labtech’s mirrorball fluorescence cytometer.
To date there is no licensed vaccine against RSV infection and the only preventative treatment option is the neutralizing anitbody palivizumab, which is given to high risk infants by passive administration[2]. Therefore there is a strong drive to identify novel RSV-neutralizing antibodies for therapeutic/preventative applications.
Here we present the development and implementation of a simple RSV-neutralization assay on TTP Labtech’s mirrorball fluorescence cytometer.
